Bob Lechleider
Technik-/Wissenschafts-/F&E-Leiter bei IMMUNOME, INC.
Profil
Bob Lechleider is currently the Chief Medical Officer at Immunome, Inc. He previously worked as the Senior Vice President-Clinical Development at Seagen Inc. and as the Chief Medical Officer at OncoResponse, Inc. from 2020 to 2023.
Dr. Lechleider completed his undergraduate degree at Princeton University and obtained a doctorate from the University of Illinois College of Medicine.
Aktive Positionen von Bob Lechleider
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNOME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.10.2023 |
Ehemalige bekannte Positionen von Bob Lechleider
| Unternehmen | Position | Ende |
|---|---|---|
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2023 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2023 |
Ausbildung von Bob Lechleider
| Princeton University | Undergraduate Degree |
| University of Illinois College of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
